---
schema_version: "secwatch.filing_event.v1"
accession: "0001425450-23-000098"
form_type: "8-K"
ticker: "KIDS"
cik: "0001425450"
company_name: "ORTHOPEDIATRICS CORP"
filed_at: "2023-07-31T23:59:59+00:00"
generated_at: "2026-06-12T21:54:51.138331+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OrthoPediatrics Q2 revenue $39.6M (+20% YoY); net loss $2.9M, FY guide reaffirmed

## Summary
- Total revenue $39.6M, +20% vs $32.9M in Q2 2022; US +19%, international +25%.
- Trauma & Deformity revenue $27.5M (+22%), Scoliosis $10.9M (+16%), Sports Med/Other $1.2M (+23%).
- Gross margin 76% (flat YoY); operating expenses $35.6M (+24%).
- Net loss $2.9M ($0.13 loss per share) vs $0.3M loss a year ago; adj. EBITDA $2.3M vs $2.1M.
- FY 2023 revenue guidance reiterated at $148M–$151M (21–23% growth); adj. EBITDA expected $3M–$4M.

## SEC filing metadata
- accession: 0001425450-23-000098
- form_type: 8-K
- ticker: KIDS
- cik: 0001425450
- company_name: ORTHOPEDIATRICS CORP
- filed_at: 2023-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425450/000142545023000098/0001425450-23-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425450/000142545023000098/kids-20230731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001425450-23-000098
- JSON: https://secwatch.observer/filing/0001425450-23-000098.json
- Plain text: https://secwatch.observer/filing/0001425450-23-000098.txt

## Key facts
- Earnings Releases
  ORTHOPEDIATRICS CORP reported the second quarter ended June 30, 2023 results: revenue $39.6 million, net income $2.9 million, EPS $0.13 per basic and diluted share. Guidance reaffirmed.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $39.6 million
  - Net income: $2.9 million
  - EPS: $0.13 per basic and diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: OrthoPediatrics Corp. Reports Second Quarter 2023 Financial Results Record Setting Quarterly Revenue of $39.6 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425450/000142545023000098/0001425450-23-000098-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.